ORIC Pharmaceuticals (ORIC) Competitors $8.33 +0.12 (+1.46%) (As of 05:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ORIC vs. NAMS, IDYA, CNTA, RXRX, IBRX, APGE, WVE, AKRO, MIRM, and TARSShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), Apogee Therapeutics (APGE), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Apogee Therapeutics Wave Life Sciences Akero Therapeutics Mirum Pharmaceuticals Tarsus Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Do analysts rate NAMS or ORIC? NewAmsterdam Pharma currently has a consensus price target of $36.20, indicating a potential upside of 41.24%. ORIC Pharmaceuticals has a consensus price target of $18.29, indicating a potential upside of 119.52%. Given ORIC Pharmaceuticals' higher probable upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, NAMS or ORIC? NewAmsterdam Pharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Do insiders and institutionals have more ownership in NAMS or ORIC? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, NAMS or ORIC? ORIC Pharmaceuticals has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$33.59M70.48-$176.94MN/AN/AORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.63 Does the MarketBeat Community prefer NAMS or ORIC? ORIC Pharmaceuticals received 41 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 72.09% of users gave ORIC Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes21100.00% Underperform VotesNo VotesORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% Is NAMS or ORIC more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A ORIC Pharmaceuticals N/A -42.47%-38.86% Does the media prefer NAMS or ORIC? In the previous week, NewAmsterdam Pharma had 7 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 17 mentions for NewAmsterdam Pharma and 10 mentions for ORIC Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 0.80 beat ORIC Pharmaceuticals' score of 0.46 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNewAmsterdam Pharma beats ORIC Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$587.82M$6.69B$5.20B$9.16BDividend YieldN/A2.99%5.12%4.27%P/E Ratio-4.6310.6787.7017.16Price / SalesN/A193.781,139.33122.80Price / CashN/A57.1643.2337.85Price / Book2.505.124.804.78Net Income-$100.70M$151.58M$120.46M$225.43M7 Day Performance1.09%0.00%-0.84%-0.68%1 Month Performance-13.14%-3.68%14.85%1.06%1 Year Performance-6.19%9.07%29.53%15.74% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals3.6851 of 5 stars$8.33+1.5%$18.29+119.5%-7.5%$587.82MN/A-4.6380News CoverageNAMSNewAmsterdam Pharma2.8172 of 5 stars$24.54-0.6%$36.20+47.5%+131.4%$2.27B$33.59M0.0057Insider TradeAnalyst RevisionIDYAIDEAYA Biosciences4.3427 of 5 stars$25.91+2.9%$53.67+107.1%-26.1%$2.24B$3.92M-10.8180CNTACentessa Pharmaceuticals2.6942 of 5 stars$16.53-0.2%$25.83+56.3%+114.5%$2.18B$6.85M-10.8372Insider TradeRXRXRecursion Pharmaceuticals2.4474 of 5 stars$7.48+7.6%$9.25+23.7%-41.6%$2.14B$44.58M-4.85400Options VolumeGap UpHigh Trading VolumeIBRXImmunityBio2.1468 of 5 stars$3.05+6.3%$17.38+469.7%-41.0%$2.13B$7.33M-3.36590Analyst ForecastAPGEApogee Therapeutics2.6134 of 5 stars$46.96+5.5%$83.88+78.6%+70.3%$2.11BN/A-18.3991WVEWave Life Sciences4.8999 of 5 stars$13.55+0.8%$22.22+64.0%+176.8%$2.07B$53.61M-12.22240AKROAkero Therapeutics4.0876 of 5 stars$29.08+0.7%$46.83+61.0%+27.1%$2.03BN/A-7.7030MIRMMirum Pharmaceuticals4.0028 of 5 stars$42.08-0.8%$57.73+37.2%+38.4%$2.02B$307.03M-21.01140Positive NewsTARSTarsus Pharmaceuticals0.3417 of 5 stars$51.77-1.4%$54.20+4.7%+167.0%$1.98B$17.45M-13.7850Positive News Related Companies and Tools Related Companies NewAmsterdam Pharma Competitors IDEAYA Biosciences Competitors Centessa Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors ImmunityBio Competitors Apogee Therapeutics Competitors Wave Life Sciences Competitors Akero Therapeutics Competitors Mirum Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORIC) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
